Literature DB >> 21213151

Pharmacological treatment for Alzheimer's disease: current approaches and future strategies.

Ling-Yun Fan1, Ming-Jang Chiu.   

Abstract

More than a decade after the first approval of the use of acetylcholine esterase inhibitor on patients with Alzheimer's disease, we still not have a single treatment or combination therapy that can effectively stop or reverse the relentless progression of such neurodegenerative disease. Recently therapeutics targeting amyloid hypothesis have undergone scrutiny by many clinical trials. These include gamma secretase inhibitor for reducing beta amyloid formation, agents for preventing aggregation of amyloid oligomers, and immunotherapy for enhancing clearance of amyloid and plaque. Therapies targeting hyperphosphorylated tau is another promising mechanism to be tackled with. Other agents enforcing mitochondria functions, enhancing serotonin receptors, modulating advanced glycation end products, and neurotrophic factors, as well as other therapies are also emerging. We review current treatments and therapeutic strategies already undergone different stage of clinical trails in this report. We propose that therapeutics of various combination composed of symptomatic treatments and disease modifying therapies will become standard regimens of AD treatment with much better efficacy than current approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21213151

Source DB:  PubMed          Journal:  Acta Neurol Taiwan        ISSN: 1028-768X


  6 in total

1.  Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.

Authors:  Andréia M Pazini; Guilherme M Gomes; Jardel G Villarinho; Claudio da Cunha; Francielle Pinheiro; Ana P O Ferreira; Carlos F Mello; Juliano Ferreira; Maribel A Rubin
Journal:  Neurochem Res       Date:  2013-09-05       Impact factor: 3.996

Review 2.  Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy.

Authors:  S C Thomas; A Alhasawi; V P Appanna; C Auger; V D Appanna
Journal:  J Nutr Health Aging       Date:  2015-01       Impact factor: 4.075

3.  Identification of microRNAs involved in Alzheimer's progression using a rabbit model of the disease.

Authors:  Qing Yan Liu; Marilyn N Vera Chang; Joy X Lei; Roger Koukiekolo; Brandon Smith; Dongling Zhang; Othman Ghribi
Journal:  Am J Neurodegener Dis       Date:  2014-03-28

4.  MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues.

Authors:  Charlotte Delay; Sébastien S Hébert
Journal:  Int J Alzheimers Dis       Date:  2011-07-31

Review 5.  Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics.

Authors:  Ioanna Petta; Sam Lievens; Claude Libert; Jan Tavernier; Karolien De Bosscher
Journal:  Mol Ther       Date:  2015-12-17       Impact factor: 11.454

6.  Cognitive improvement of compound danshen in an Aβ25-35 peptide-induced rat model of Alzheimer's disease.

Authors:  Min Liu; Haibiao Guo; Chuyuan Li; Deqin Wang; Jingang Wu; Canmao Wang; Jiangping Xu; Ren-An Qin
Journal:  BMC Complement Altern Med       Date:  2015-10-23       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.